Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Genetic risk model to predict outcomes for AML treated with HMA and venetoclax

View Full Paper
Ask AI
Bookmark
Share

Authors

RSRafeh SafdarJHJonah HeidelYAYanal Alnimer

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows genetic risk factors predict overall survival in AML patients receiving venetoclax and hypomethylating agents.

Key Points

  • To develop a genetic risk model for predicting outcomes in acute myeloid leukemia patients treated with hypomethylating agents and venetoclax.
  • Retrospective analysis of adult AML patients treated with HMA and venetoclax at a cancer center.
  • Used demographic and genetic data for model construction.
  • Analyzed outcomes using Kaplan–Meier and Cox proportional hazards methods.
  • 71% of patients achieved composite remission, with 43% relapsing over a median follow-up of 21.7 months.
  • NPM1 mutation was associated with improved relapse-free survival; TP53 mutation predicted reduced survival.
  • A novel genetic risk model effectively stratified patients into low-, intermediate-, and high-risk groups based on genetic profiles.

Cite This Study

Safdar et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d359https://doi.org/10.1182/blood-2025-1708
View Full Paper
Ask AI
Bookmark
Share